Weaker expectations for the oil & gas business
07/11/19 -"This led to an impairment (92% for goodwill) on the former Rhodia and Chemlogics activities (Novecare – Advance Formulations), which damaged the Q3 figures and came fully out of the blue. In ..."
Pages
59
Language
English
Published on
07/11/19
You may also be interested by these reports :
24/10/25
The change in the target price is due to a change in the analyst covering the stock, complemented by the usage of systematic intrinsic and peer-based ...
22/10/25
Akzo Nobel’s Q3 2025 results were broadly in line, with moderate growth in Decorative Paints supported by China and Latin America, partly offset by ...
22/10/25
At the beginning of Spring 2024, our caution on Johnson Matthey (Reduce, UK) reflected our concerns over the lack of clear growth drivers. As metal ...
20/10/25
The change in the target price is due to a change in the analyst covering the stock.